Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China

Fig. 4

Cost-effectiveness acceptability curves. Vertical axis shows the probability that 50% efficacy, 10-year duration of protection pre-and post-infection (PΠ top) and post-infection (PSI; bottom) vaccines are cost-effective at or below a given willingness to pay value (horizontal axis), in India (left) and China (right). Reference lines are 2018 World Bank GDP and upper and lower health-care opportunity-cost thresholds. Note: x-axis scales differ between subplots

Back to article page